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Abstract Background: Acute
renal failure on the intensive care
unit is associated with significant
mortality and morbidity.
Objectives: To determine recom-
mendations for the prevention of
acute kidney injury (AKI), focusing
on the role of potential preventa-
tive maneuvers including volume
expansion, diuretics, use
of inotropes, vasopressors/vasodi-
lators, hormonal interventions,
nutrition, and extracorporeal
techniques. Method: A systematic
search of the literature was per-
formed for studies using these
potential protective agents in adult
patients at risk for acute renal fail-
ure/kidney injury between 1966 and
2009. The following clinical condi-
tions were considered: major
surgery, critical illness, sepsis,
shock, and use of potentially neph-
rotoxic drugs and radiocontrast
media. Where possible the following
endpoints were extracted: creatinine
clearance, glomerular filtration rate,
increase in serum creatinine, urine
output, and markers of tubular
injury. Clinical endpoints included
the need for renal replacement
therapy, length of stay, and mortal-
ity. Studies are graded according to
the international Grades of Recom-
mendation, Assessment,
Development, and Evaluation
(GRADE) group system Conclusions
and recommendations: Several
measures are recommended, though
none carries grade 1A. We recom-
mend prompt resuscitation of the
circulation with special attention to
providing adequate hydration whilst
avoiding high-molecular-weight
hydroxy-ethyl starch (HES) prepa-
rations, maintaining adequate blood
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pressure using vasopressors in
vasodilatory shock. We suggest
using vasopressors in vasodilatory
hypotension, specific vasodilators
under strict hemodynamic control,
sodium bicarbonate for emergency
procedures administering contrast
media, and periprocedural hemofil-
tration in severe chronic renal
insufficiency undergoing coronary
intervention.
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Introduction
Acute kidney injury (AKI) often complicates the course
of critical illness and, although previously considered as
a marker rather than a cause of adverse outcomes, it is
now known to the extent possible to be independently
associated with an increase in both morbidity and mor-
tality [1–11]. The major causes of AKI in the intensive
care unit (ICU) include renal hypoperfusion, sepsis/sys-
temic inflammatory response syndrome (SIRS), and
direct nephrotoxicity, although in most cases etiology is
multifactorial [12–15]. Furthermore, epidemiological
studies involving patients undergoing cardiothoracic
surgery [16, 17] or contrast administration [18, 19] have
determined additional risk factors including age, preex-
isting hypertension, diabetes mellitus, heart failure, and
prolonged and complex surgery. It follows that mini-
mizing renal injury should confer a benefit to patients.
This review is the result of an international collabo-
ration of the Critical Care Nephrology Working Group of
the European Society of Intensive Care Medicine
(ESICM) with the principal aim of providing a critical
evaluation of available evidence and to give recommen-
dations, where possible, for clinical practice. We have
focused primarily on the role of volume expansion,
diuretics, inotropes, vasopressors/vasodilators, hormonal
interventions, nutrition, and extracorporeal techniques,
which are the major interventions routinely and easily
undertaken in intensive care practice.
Methods
A systematic search of the literature was performed using
the following databases: Medline (1966 through 2009,
April), Embase (1980 through 2009, week 15), CINAHL
(1982 through 2009, April), Web of Science (1955 through
2009), and PubMed/PubMed Central to identify key
studies, preferably randomized placebo-controlled trials
(RCT) and meta-analyses, on AKI/acute renal failure
(ARF) addressing the use of therapeutic strategies to
prevent renal dysfunction in adult critically ill patients.
The following clinical conditions were considered: major
surgery, critical illness, sepsis, shock, and use of potentially
nephrotoxic drugs and radiocontrast. Transplantation,
primary renal disease (e.g., vasculitis), and the hepatorenal
syndrome were not considered.
Search terms and text words are available in electronic
supplementary material (ESM), as are the endpoints
extracted.
These recommendations are intended to provide
guidance for the clinician caring for a patient at risk of
AKI. The process of developing these recommendations
included a modified Delphi process, three nominal con-
sensus conferences during the annual meetings of the
European Society of Intensive Care Medicine 2005 and
2006, followed by electronic-based discussions. The
quality of the evidence was judged by predefined Grades
of Recommendation, Assessment, Development, and
Evaluation (GRADE) criteria, which has also been
employed in developing the latest Surviving Sepsis
international guidelines [20]. This allows the develop-
ment and grading of management recommendations
through rating the quality of available evidence and
grading strength of recommendations in clinical practice,
as described in more detail elsewhere [21].
According to the GRADE system the strength of the
recommendations is classified as either strong (1) or weak (2)
[22]. A strong recommendation (1) indicates that an inter-
vention’s desirable effects clearly outweigh undesirable
effects such as risk, cost, and other burdens. Weak recom-
mendations (i.e., suggestions) (2) indicate that the balance
between undesirable and desirable effects is less clear.
The degree (i.e., quality) of evidence for the recom-
mendations is classified from high (A) to low (C)
according to factors including study design, consistency of
the results, and directness of the evidence [22]. We
regarded repeated large RCTs including C50 patients in
each arm and meta-analyses showing low heterogeneity as
providing a high degree of evidence (A) and smaller RCTs
or larger RCTs whose results could not be reproduced as
providing lower-grade evidence (B). For clinical decision-
making, the grade of recommendation is considered of
greatest clinical importance. It should, however, be
emphasized that there may be circumstances in which a
recommendation cannot or should not be followed for an
individual patient. Furthermore, interventions are gener-
ally investigated separately, not in combination, and as
such recommendations relate to the primary intervention.
Local clinical guidelines will govern the use of either a
single intervention or a combination.
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Volume expansion
Recommendations
1. We recommend controlled fluid resuscitation in true
or suspected volume depletion (grade 1C).
2. There is little evidence-based support for the prefer-
ential use of crystalloids, human serum albumin,
gelatine-derived colloids or the lowest-molecular-
weight hydroxy-ethyl starches (HES) for renal protec-
tion as long as derangements of serum electrolytes are
prevented.
3. We recommend avoiding 10% HES 250/0.5 (grade 1B)
as well as higher-molecular-weight preparations of HES
and dextrans in sepsis (grade 2C).
4. We recommend prophylactic volume expansion by
isotonic crystalloids in patients at risk of contrast
nephropathy (grade 1B). We suggest using isotonic
sodium bicarbonate solution, especially for emergency
procedures (grade 2B).
5. We suggest prophylactic volume expansion with
crystalloids to prevent AKI by certain drugs (specified
below) (grade 2C).
Rationale
Both relative and overt hypovolemia are significant risk
factors for the development of AKI [23–26]. Conse-
quently, timely fluid administration is a preventive
measure which should be effective both through restora-
tion of circulating volume and minimizing drug-induced
nephrotoxicity [27]. Where volume replacement is indi-
cated, this should be performed in a controlled fashion
directed by hemodynamic monitoring, as injudicious use
of fluids carries its own inherent risk [26]. In the ICU
patient this may manifest in several ways, including
prolonged mechanical ventilation [28] or the development
of intra-abdominal hypertension, which itself is a risk
factor for AKI [29].
Volume replacement may employ 5% glucose (i.e.,
free water), crystalloids (isotonic, half-isotonic), colloids,
or more commonly in clinical practice, a combination
thereof. Glucose solutions substitute free water and are
used to correct hyperosmolar states, although the main-
stay for correction of extracellular volume depletion
remains isotonic crystalloids. However, the increased
chloride load may result in hyperchloremic acidosis and
associated renal vasoconstriction as well as altered per-
fusion of other organs such as the gut [30]. Crystalloids
expand plasma volume by approximately 25% of the
infused volume, whereas colloid infusion results in a
greater expansion of plasma volume. The degree of
expansion is dependent on concentration, mean molecular
weight, and (for HES) the degree of molecular substitu-
tion. However, large-volume replacement with colloids in
isolation risks hyperoncotic impairment of glomerular
filtration [31, 32] as well as osmotic tubular damage,
particularly in sepsis [33–35].
Commonly employed colloids include human albumin
(HA), gelatins, dextranes, and HES. HA may appear
attractive in hypooncotic hypovolemia but is costly [36–
38]. A large multicenter RCT comparing 4% albumin
with crystalloid failed to demonstrate any difference in
outcome parameters including renal function, but proved
that albumin itself was safe [39]. Gelatines have an
average molecular weight of ca. 30 kDa, and the observed
intravascular volume effect is shorter than that observed
with HA or HES. Advantages include the lack of dele-
terious effects on renal function [40, 41] offset by the
possibility of prion transmission, histamine release, and
coagulation problems, particularly if large volumes are
infused [42, 43]. Dextrans are single-chain polysaccha-
rides comparable to albumin in size (40–70 kDa) and with
a reasonably high volume effect, although anaphylaxis,
coagulation disorders, and indeed AKI may occur at doses
higher than 1.5 g/(kg day) [44–47]. HES are highly
polymerized sugar molecules characterized by molecular
weight, grade of substitution, concentration, and C2/C6
ratio. Their volume effect is greater than that of albumin,
especially when larger-sized polymers are employed
which degrade through hydrolytic cleavage the products
of which undergo renal elimination. These degradation
products may be reabsorbed and contribute to osmotic
nephrosis and possibly medullary hypoxia [35, 48]. A
further problem with HES may be tissue deposition and
associated pruritus, which appears to be dose dependent
[49–51]. These adverse effects may be less pronounced in
the more modern, rapidly degradable HES solutions such
as HES 130/0.4 [52–54].
Clinical studies
Unsurprisingly, no studies have specifically addressed the
effects of volume expansion in overt hypovolemia com-
pared with no volume resuscitation given the intuitive
benefits of volume replacement. A large prospective
observational trial of the CRYCO (CRYstalloids or
COlloids?) study group found an increased risk of AKI in
1,013 ICU patients with shock receiving either hyperon-
cotic artificial colloids or albumin as compared with
crystalloids [55]. This is in contrast to the results of a
large RCT comparing isotonic sodium chloride to human
serum albumin in various clinical settings, where no dif-
ferences in renal function were demonstrated [39] (ESM
Table S1). Given the lack of a marked beneficial effect
the use of albumin should be limited given its expense.
Small studies performed in the perioperative setting
have compared a variety of fluid replacement regimes
(mainly between various forms of HES, or HES versus
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gelatine or albumin) with no definitive conclusions [56–
60]. Only one RCT reported better preserved early post-
operative renal function with 6% HES 130/0.4 than with
4% gelatine following cardiac surgery [61].
In patients undergoing low-risk surgery with normal
renal function, a small RCT comparing lactated Ringers’
solution to three different forms of HES demonstrated no
adverse effects of either solution [62].
In severe sepsis the beneficial effects of timely vol-
ume replacement on organ failure and mortality are well
known and are a cornerstone of the Surviving Sepsis
campaign guidelines [20, 63]. A single-center RCT
comparing 5% HA with gelatine in ICU patients showed
no difference in renal function despite significant dif-
ferences in serum albumin levels [64]. A study
comparing 6% HES 200/0.5 with gelatine in ICU
patients with sepsis demonstrated slightly lower serum
creatinine levels in the group receiving gelatine, but no
effect was observed on endpoints such as the need for
renal replacement therapy (RRT) or mortality [41] (ESM
Table S1). However, a large German RCT in patients
with septic shock (the VISEP trial) showed a higher
incidence of AKI, requirement for RRT, and mortality in
the group treated with 10% HES 200/0.5 compared with
Ringer’s lactate [65]. Adverse effects on renal function
may be restricted to higher-molecular-weight HES, as a
multivariate analysis in a large European multicenter
observational study was unable to detect HES as an
independent risk factor, neither in 1,970 ICU patients
requiring RRT nor in a subgroup of 822 patients with
severe sepsis [66].
Prophylactic volume expansion has been investigated
extensively in the setting of contrast-induced nephrop-
athy (CIN) [67–72]. The benefit of this measure has
been mainly shown for patients with inherent risk fac-
tors of CIN such as reduced glomerular filtration rate
(GFR) (\50 ml/min/1.73 m2), heart failure or diabetes
characterized by various risk scores (e.g., Thakar score
[18] or Mehran score [19]). The first RCT comparing
protection in CIN by half normal saline versus half
normal saline plus diuretic therapy clearly demonstrated
the superiority of volume expansion by half normal
saline at a rate of 1 ml/kg 12 h before and after angi-
ography [67]. However, a larger RCT including 1,620
patients undergoing coronary angioplasty showed a
lower incidence of CIN when using normal saline
compared with half normal saline [68]. Given that
normal saline contains a high amount of chloride, the
protective effect of isotonic bicarbonate solutions (con-
taining 150–154 mmol/l sodium) in patients with
impaired renal function receiving contrast agents has
been studied. This showed a significant reduction in the
incidence of CIN [69–75], but not in the need of renal
replacement therapy or mortality. Most investigations
applied a hydration regimen starting at 3(–5) ml/(kg h)
1 h before radiocontrast application, followed by 1 ml/(kg h)
for at least 6 h post procedure [69, 71–73, 75]. Although
three recent RCTs indicated that hydration with saline
or sodium bicarbonate were equally effective [76–78],
when included in meta-analyses a benefit of sodium
bicarbonate over normal saline could still be detected
[74, 79–81] (ESM Table S2). In a recent RCT of cardiac
surgical patients at risk for AKI, intravenous sodium
bicarbonate was associated with a lower incidence of
acute renal dysfunction [82]. Nevertheless, adequately
powered RCTs are still needed to determine whether
sodium bicarbonate will reduce clinically meaningful
outcomes.
Hypovolemia may also contribute significantly
towards drug-induced renal injury, although the available
evidence supporting preventative hydration is observa-
tional with no consensus found as to the timing, optimal
volume, and type of solution to be employed [12]. Pre-
vention of nephrotoxicity through prophylactic volume
expansion has been shown to be of benefit with ampho-
tericin B, antivirals including foscarnet, cidofovir, and
adefovir [83–85], as well as drugs causing crystal
nephropathy such as indinavir, acyclovir, and sulfadiazine
[86].
Diuretics
Recommendations
1. We recommend that loop diuretics are not used to
prevent or ameliorate AKI (grade 1B).
Rationale
Oligo-anuria frequently is the first indicator of acute renal
dysfunction. A multinational survey has demonstrated
that 70% of intensivists used loop diuretics in a wide
spectrum of AKI settings [87]. There may indeed be some
theoretical attractions in using diuretics to ameliorate
AKI, including prevention of tubular obstruction, reduc-
tion in medullary oxygen consumption, and increase in
renal blood flow [88–90].
Clinical studies
Few prospective randomized trials have addressed the
role of diuretics in the prevention of AKI. Most of the
available studies have been done in the setting of contrast
administration [67, 91, 92] and cardiac surgery [93, 94].
No protection against contrast nephropathy has been
observed with diuretics, and in cardiac surgery, higher
postoperative serum creatinine levels were found in
patients receiving furosemide [93, 94].
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To date four randomized controlled trials have
examined the role of diuretics in established renal fail-
ure in the intensive care setting. No demonstrable
improvement in primary outcome parameters, such as
recovery of renal function or mortality, has been
observed [35, 95–97]. Other studies have compared
diuretics with dopamine or against placebo, again with
no perceived benefit [33, 98, 99]. Three meta-analyses
confirmed that the use of diuretics in established AKI
does not alter outcome but carries a significant risk of
side-effects such as hearing loss [100–102] (ESM
Table S3). Furthermore, in an international cohort study
an increase in the risk of death or an increase in
established renal failure was observed. These findings,
however, could not be confirmed in a second cohort
study [103, 104].
Vasopressors and inotropes
Recommendations
1. We recommend that mean arterial pressure (MAP) be
maintained C60–65 mmHg (grade 1C), however, tar-
get pressure should be individualized where possible,
especially if knowledge of the premorbid blood pres-
sure is available.
2. In case of vasoplegic hypotension as a result of sepsis
or SIRS we recommend either norepinephrine or
dopamine (along with fluid resuscitation) as the first-
choice vasopressor agent to correct hypotension
(grade 1C).
3. We recommend that low-dose dopamine not be used
for protection against AKI (grade 1A).
Rationale
Preservation or improvement of renal perfusion can the-
oretically be achieved by fluid resuscitation, through renal
vasodilators, by systemic vasopressors that redirect blood
flow to the kidney or by increasing cardiac output through
the use of inotropic drugs. Whereas a recent study indi-
cated that any MAP of C60 mmHg may be considered
adequate for patients with septic shock [105], additional
benefits with regards to renal function were not observed
when a target MAP of more than 85 mmHg was compared
to a target of 65 mmHg [106]. However, it must be borne
in mind that this study may not be widely applicable to
the patients admitted to the intensive care unit with pre-
existing comorbidities. Those at greatest risk of
developing AKI include those patients with vascular
disease, hypertension, diabetes, increased age, and ele-
vated intra-abdominal pressure, for whom the target mean
arterial pressures may have to be individually tailored.
Clinical studies
Low-dose or ‘‘renal-dose’’ dopamine has been advocated
in the past to prevent selective renal vasoconstriction in a
variety of conditions [107]. Although dopamine infusion
may improve renal perfusion in healthy volunteers, no
improvement of renal perfusion nor preventive benefit
with respect to renal dysfunction has been unequivocally
demonstrated in the critically ill, where increased sym-
pathetic activity and local norepinephrine release may
contribute to renal vasoconstriction [108–110]. Dopamine
also has an inotropic effect, but observed increases in
diuresis or even a reduction in serum creatinine during
dopamine infusion does not protect against AKI [107,
110, 111]. Several meta-analyses have concluded that
‘‘renal-dose’’ dopamine is of no benefit in either pre-
venting or ameliorating AKI in the critically ill and may
even promote AKI [107, 109, 112].
The inotropic agents dobutamine and dopexamine
have also been examined, but to date no prospective
controlled clinical trial has demonstrated a protective
effect on renal function [113]. In contrast, the effect of
dobutamine on renal function is variable, even when
favorably affecting cardiac output [111].
Norepinephrine is known to be of use in the treatment
of vasodilatory shock after adequate fluid loading. In
nonrandomized studies, administration of norepinephrine
and resulting increases in arterial blood pressure have
shown to increase diuresis and creatinine clearance [114].
Whether this is due to increased renal perfusion and thus
implies renal protection is unknown. A RCT on 252 adult
patients comparing dopamine in septic shock with nor-
epinephrine as the initial vasopressor showed no
significant differences between groups with regard to
renal function or mortality. Though norepinephrine was
associated with significantly less sinus tachycardia and
arrhythmias (Patel GP et al., Shock, in press).
Vasopressin is gaining popularity in the treatment of
norepinephrine-refractory shock [115] increasing blood
pressure and enhancing diuresis in hypotensive oliguric
patients but as yet has not been proven to enhance survival
nor to prevent or ameliorate AKI in the critically ill [116].
Vasodilators
Recommendations
1. We suggest using vasodilators for renal protection
when volume status is corrected and the patient is
closely hemodynamically monitored with particular
regard to the development of hypotension (grade 2C).
When choosing a vasodilator, the clinical condition of
the patient, the availability of the drug, and the con-
comitant interventions should be considered.
396
2. We suggest the prophylactic use of fenoldopam, if
available, in cardiovascular surgery patients at risk of
AKI (grade 2B). We recommend that fenoldopam is
not used for prophylaxis of contrast nephropathy
(grade 1A).
3. We suggest using theophylline to minimize risk of
contrast nephropathy, especially in acute interventions
(grade 2C) when hydration is not feasible.
4. We suggest that natriuretic peptides are not used as
protective agents against AKI in critically ill patients
(grade 2B), while its use may be considered during
cardiovascular surgery (grade 2B).
Rationale
Reduced tissue perfusion elicits neurohumoral activation
leading to increased sympathetic tone, endothelin pro-
duction, and activation of the renin–angiotensin–
aldosterone system which maintains systemic blood
pressure often at the cost of both splanchnic and renal
vasoconstriction. Glomerular perfusion and filtration
pressure are maintained through afferent arteriolar vaso-
dilatation and efferent vasoconstriction, but once these
compensatory mechanisms fail, a decline in glomerular
filtration ensues. This critical threshold for renal perfusion
depends on the ability of compensatory intrarenal vaso-
dilatation. It is increased, for example, with chronic
hypertension and high venous pressure states and
decreased by endogenous or exogenous vasodilators
[117–121]. In circumstances of persistent renal vasocon-
striction, vasodilators might have a beneficial effect on
kidney function. However, the use of vasodilators may
cause hypotension by counteracting compensatory vaso-
constriction, thus unmasking occult hypovolemia, and as
such the correction of hypovolemia is crucial.
Clinical studies
Fenoldopam is a pure dopamine A-1 receptor agonist.
Three RCTs have evaluated the effects of continuous
infusion of fenoldopam on renal function in critically ill
patients with AKI and observed mixed results [122–124].
Two compared fenoldopam with placebo, and one with
dopamine. In one, fenoldopam was found to be beneficial
with regard to the primary endpoints of dialysis-free
survival at 21 days and need of RRT in the selected
subgroups of patients without ‘‘diabetes mellitus’’ or
‘‘after cardiac surgery’’ [124]. In another, fenoldopam
caused a significant decrease in mild AKI (defined as a
rise in serum creatinine[150 lmol/L) and ICU stay, and
a nonsignificant decrease in severe AKI (serum creatinine
[300 lmol/L) [123]. In the third, infusion of fenoldo-
pam, but not dopamine, over 4 days significantly reduced
serum creatinine [122]. Prophylactic administration of
fenoldopam has been studied during surgery and follow-
ing administration of radiocontrast. A meta-analysis
including 1,059 patients undergoing cardiovascular sur-
gery found that fenoldopam consistently and significantly
reduced the need for RRT and in-hospital mortality [125].
A second meta-analysis including 1,290 critically ill and
surgical patients from 16 randomized studies reported that
the use of fenoldopam reduced the incidence of acute
renal injury, need for RRT, and hospital mortality [126].
However, none of the larger RCTs showed that using
fenoldopam for the prevention of contrast nephropathy
confers renal protection [127, 128] (studies summarized
in ESM Table S4).
Clonidine is a central and peripheral adrenergic-
receptor blocking agent with predominantly a2 blocking
effects which also reduces plasma renin levels. Two
RCTs, again involving cardiothoracic patients demon-
strated some beneficial effects of clonidine on renal
function [129, 130]. However, the use of b-blockers as
part of current practice is not mentioned in these studies
(ESM Table S5).
Anaritide (ANP) is produced by cardiac atria in
response to atrial dilatation and induces afferent glomer-
ular dilatation and efferent vasoconstriction as well as
increasing urinary sodium excretion, renal blood flow,
and GFR in early ischemic AKI with a dose-dependent
hypotensive effect [131]. Ularitide and nesiritide (brain
natriuretic peptide, BNP) have similar effects. The first
large RCT evaluating ANP in AKI found a reduction of
RRT in the oliguric subgroup only [132]. Disappointing
results were subsequently observed in RCTs of anaritide
and ularitide in patients with oliguric AKI [133–135]. In
contrast, a RCT in post cardiac surgery patients with heart
failure and early renal dysfunction demonstrated that use
of continuous low-dose anaritide significantly reduced the
need for RRT [136]. The effect of nesiritide was even
more pronounced in cardiac surgery patients with reduced
ejection fraction (NAPA trial), demonstrating shorter
hospital stay and reduced 180-day mortality [137]. The
observed differences might be explained by differences in
dose and duration of drug administration with a conse-
quent reduction in hypotension observed. Similarly,
protective effects on renal function were observed with
low-dose nesiritide in elective abdominal aneurysm repair
[138] and in cardiac bypass surgery [139]. Of note, a
recent meta-analysis comparing non-inotrope-based
treatment with nesiritide (h-BNP) therapy indicated that
this may be associated with an increased risk of renal
failure and death in a select population of patients with
acutely decompensated heart failure [140] (ESM
Table S6).
Phosphodiesterase (PDE) inhibitors have both vasod-
ilatory and inotropic effects and modulate the
inflammatory response, rendering them interesting can-
didates for the prevention of renal damage. Ten controlled
trials evaluating the effect of theophylline on the
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prevention of contrast nephropathy showed varying effi-
cacy in attenuating increases in serum creatinine after
administration of radiocontrast media [141–151]. The
results of three successive meta-analyses remained
inconclusive [142, 147, 152]. However, a more recent
trial has demonstrated a reduction in the incidence of
contrast nephropathy by preprocedural administration of
200 mg theophylline in critically ill patients [151].
Anticipated adverse events such as arrhythmias were not
observed (ESM Table S7).
Pentoxifylline has been examined in low risk cardio-
thoracic patients with no benefit [153] but other small
studies examined populations at higher risk and demon-
strated beneficial effects on both preservation of renal
function and clinical outcomes [154, 155].
Enoximone is a selective phosphodiesterase III
inhibitor with both vasodilatory and anti-inflammatory
properties. Two small studies in cardiac surgery have
evaluated the effect of enoximone, with one study com-
bining enoximone with the b-blocker esmolol [156, 157].
Both demonstrated a reduction in post-bypass inflamma-
tion and renal protective effects, although the studies were
not designed to show effects on clinical outcomes.
A new phosphodiesterase inhibitor with myocardial
calcium sensitizer activity, levosimendan, has recently
been approved for the treatment of congestive cardiac
failure. A small RCT in 80 patients with acute decom-
pensated heart failure demonstrated short-term
improvement of renal function as measured by eGFR
which could not be achieved by dobutamine alone [158].
The compensatory release of the vasodilator prosta-
glandin PGE1 contributes to the maintenance of renal
perfusion through dilatation of both the afferent arteriole
and medullary vessels in renal hypoperfusion. Three
clinical studies showed a mild protective effect of vaso-
dilator prostaglandins (PGE1/PGI2) [159–161].
Angiotensin blockade may have renal protective
effects in the acute setting; for example, angiotensin
blockade augments renal cortical microvascular PO2
[162] and restores endothelial dysfunction [163]. Two
studies evaluating the effect of short-term intravenous
enalaprilat in a cardiac surgical population with poor
cardiac function demonstrated improved cardiac and renal
function [164, 165].
Hormonal manipulation and activated protein C
Recommendations
1. We recommend against the routine use of tight gly-
cemic control in the general ICU population
(grade 1A). We suggest ‘‘normal for age’’ glycemic
control with intravenous (IV) insulin therapy to pre-
vent AKI in surgical ICU patients (grade 2C), on
condition that it can be done adequately and safely
applying a local protocol which has proven efficacy in
minimizing rate of hypoglycemia.
2. We suggest not to use thyroxine (grade 2C), erythro-
poietin (grade 2C), activated protein C (grade 2C) or
steroids (grade 2C) routinely to prevent AKI.
Rationale
The effects of blood glucose control with insulin on the
development or progression of nephropathy in patients
with type I and type II diabetes is well documented [166].
In animal models, insulin-like growth factor 1 (IGF-1) has
been shown to accelerate recovery from ischemic and
cisplatin-induced AKI [167–169], through either renal
hemodynamic actions or through a direct metabolic,
mitogenic, and antiapoptotic effect on injured tubular
cells. Thyroid hormone has also been seen to accelerate
renal recovery in various animal models of AKI [170,
171]. There is increasing experimental evidence from
ischemia/reperfusion models that erythropoietin (EPO)
reduces apoptotic cell death and induces tubular prolif-
eration [172–175]. A retrospective clinical study also
showed a slowing of the progression of chronic renal
failure in predialysis patients [176]. However, erythro-
poietin in high doses may induce renal vasoconstriction,
systemic hypertension, increase the risk of thrombosis,
and increase tumor burden, limiting clinical applicability
[177]. New derivatives of EPO that are devoid of hema-
topoietic activity may be safer [178].
Activated protein C (APC) has pleiotropic actions
including anticoagulation, profibrinolysis, anti-inflamma-
tion, and antiapoptosis activity, and may therefore be an
ideal candidate to prevent ischemia/reperfusion-induced
organ failure. Indeed, animal models of ischemia/reper-
fusion and sepsis have documented beneficial effects on
kidney function [179–182].
Clinical studies
A large prospective randomized controlled trial in 1,548
surgical ICU patients compared tight blood glucose
control with insulin (blood glucose 80–110 mg/dL)
versus standard care (insulin therapy when blood glu-
cose [200 mg/dL resulting in mean blood glucose of
150–160 mg/dL) and showed not only an improved sur-
vival rate but also a 41% reduction in AKI requiring RRT.
Additionally, tight glucose control also reduced by
27% the number of patients with peak plasma creatinine
[2.5 mg/dL [183]. A similar study was undertaken in the
medical ICU of the same hospital where tight blood
glucose control again improved survival of prolonged
ICU stay but had no effect on the need for RRT.
However, there was a 34% reduction in newly acquired
renal injury, defined as a doubling of serum creatinine
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compared with the admission level [184]. A combined
analysis of the two clinical trials, using modified Rifle
criteria, showed a more pronounced renal protection when
normoglycemia was achieved. The absence of a reduction
in the need for RRT in medical patients could be
explained by the higher illness severity with more renal
dysfunction on admission, precluding an impact of this
mainly protective intervention [185]. Two large sequen-
tial cohort studies, one in a medical-surgical ICU [186]
and the other in the setting of cardiac surgery [187], also
revealed a significant reduction in observed renal dys-
function after the implementation of tight glycemic
control. Finally, a recent meta-analysis indicated that
survival benefit by applying tight glycemic control, if any,
may be restricted only to patients in surgical ICUs [188].
More recent randomized trials in septic [65] and
general [189, 190] ICU patients and a meta-analysis [191]
do not confirm the renoprotective effect of intensive
insulin therapy as evaluated by the need for RRT only.
A major obstacle to the broad implementation of tight
glycemic control is the increased risk of hypoglycemia. If
the clinician decides to adopt tight glycemic control then
steps should be taken to ensure that fluctuations in glucose
levels are minimized and standardized and that reliable
tools to measure blood glucose are employed [192]. An
important concern is the fact that the NICE-Sugar trial
found a higher mortality in patients treated with tight
glycemic control compared with an intermediate level,
which was found independent from hypoglycemia [190].
The clinician should, however, be aware of important
differences between the Leuven and the NICE-Sugar trial
[192] (ESM Table S8).
The use of IGF-1 has not been exposed to as much
scrutiny. A multicenter RCT in 72 patients with AKI
failed to show an effect of IGF-1 on renal recovery [193].
A small RCT of IGF-1 administered postoperatively in 54
patients undergoing vascular surgery versus placebo did
reveal a lower proportion of patients developing renal
dysfunction (fall in GFR compared with baseline), but no
difference in need for dialysis or creatinine at discharge
was observed [194].
The role of thyroxine has been examined in one RCT
in 59 patients with AKI. No effect of thyroxine on any
measure of AKI severity compared with placebo was
found [195].
With regard to the use of corticosteroids for renal
protection one small RCT (n = 20) has been performed
on patients undergoing on-pump cardiothoracic surgery.
This failed to demonstrate any effect of dexamethasone
on the transient renal impairment observed in the post-
operative period [196].
Treatment with APC reduces mortality of patients
with severe sepsis [197]. A post hoc analysis of secondary
endpoints of this trial, however, failed to show an effect
on the resolution of renal failure (measured with the
SOFA score criteria) in patients with renal dysfunction at
baseline. In patients with normal renal function at base-
line there was also no effect on the development of renal
impairment [198].
No RCT has evaluated the effect of erythropoietin in
AKI. A RCT trial on EPO in critically ill patients showed
no difference in the incidence of AKI (mentioned as an
adverse event, not as an outcome parameter) [199]. A
retrospective cohort study in 187 critically ill patients
requiring RRT used a propensity-adjusted analysis and
found an improvement in renal recovery in patients
administered EPO [198].
Metabolic interventions
Recommendations
1. We suggest that all patients at risk of AKI have ade-
quate nutritional support, preferably through the
enteral route (grade 2C).
2. We suggest that N-acetylcysteine is not used as
prophylaxis against contrast induced nephropathy or
other forms AKI in critically ill patients because of
conflicting results, possible adverse reactions, and
better alternatives (grade 2B).
3. We recommend against the routine use of selenium to
protect against renal injury (grade 1B).
Rationale
Metabolic factors are crucial for maintaining cellular
integrity and organ function, and nutrition is a basic
requirement in the care of any critically ill patients.
Starvation accelerates protein breakdown and impairs
protein synthesis in the kidney, whereas refeeding might
exert the opposite effects and promote renal regeneration.
For example, in animal experiments increased protein
intake has been shown to reduce tubular injury [200, 201].
Arginine (possibly by producing nitric oxide) helps to
preserve renal perfusion and tubular function in both
nephrotoxic and ischemic models of AKI. However,
amino acids infused before or during ischemia may also
enhance tubular damage and accelerate loss of renal
function [202]. In part, this ‘‘amino acid paradox’’ is
related to the increase in metabolic work for transport
processes which may aggravate ischemic injury. How-
ever, amino acids per se do not exert intrinsic nephrotoxic
effects.
One aspect of nutrition is the adequate supply of
nutritional cofactors and antioxidant. The role of reactive
oxygen species (ROS) under both normal and pathologi-
cal conditions has undergone much scrutiny with the
NAD(P)H oxidase system believed to be pivotal in their
formation and instrumental in the development of certain
pathophysiological conditions in the kidney [203–206].
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Under certain specific circumstances a role for antioxidant
supplementation may be proposed, with potential candi-
dates being the modified form of cysteine, N-acetylcysteine
(NAC), the antioxidant vitamins [vitamin E (a-tocopherol)
and vitamin C (ascorbic acid)], as well as selenium and
other novel antioxidants.
Clinical studies
Protein(s) and amino acids, including glutamine, augment
renal perfusion and improve renal function, a fact which
was termed ‘‘renal reserve capacity’’ [207]. However, this
potential beneficial effect has received little attention in
terms of prevention and therapy of AKI to date. Intrave-
nous amino acids appear to improve renal plasma flow
and glomerular filtration rate in cirrhotic patients with
functional renal failure [208]. One study has reported on a
positive effect of enteral versus parenteral nutrition on the
resolution of AKI [209].
Most studies on antioxidants have centered on NAC,
which besides being an antioxidant, also has a vasodila-
tory effect [210]. NAC undergoes rapid first-pass
metabolism through deacylation and as a result its bio-
availability is low even following IV administration.
There is no evidence that administration of NAC increa-
ses glutathione concentrations in the kidney [211, 212].
NAC has mainly been studied in the setting of contrast
nephropathy following the initial publication by Tepel
et al. [213] which provided the catalyst for the subsequent
proliferation of similar studies [127, 213–222]. This
subject continues to generate much research and has led
to several meta-analysis [152, 223–228] (ESM Table S9).
Most report a risk reduction, although study heterogeneity
and positive reporting bias somewhat hinders definitive
recommendations [229]. However, studies demonstrating
a positive effect have a higher incidence of CIN in the
control arms, reflecting differences in risk profile, the
route of NAC administration, the dose, the timing (with
earlier dosing perhaps being more efficacious), and the
total contrast load given. Importantly, some investigators
suggest that the reduction in serum creatinine with NAC
may be a direct effect of the drug on the creatinine
measurement and does not reflect a decrease of GFR,
although subsequent work has not replicated these find-
ings when serum creatinine is measured via the Jaffe
method [230, 231]. An issue of concern is also the fact
that the endpoint used in all the studies is a change
in creatinine and not clinically relevant endpoints such as
a need for RRT, length of stay or death. This is corrob-
orated by a recent study where contrast-induced AKI was
not independently associated with death and had no effect
on other clinical events [6, 219]. In patients stratified as
high or low risk based on GFR, NAC conferred some
benefit when combined with hydration, with multivariate
analysis confirming age, volume of contrast, diabetes, and
peripheral vascular disease as significant factors for CIN
development [232]. However, no benefit was observed in
studies using NAC in vascular patients [233, 234] nor in
diabetic patients when compared with hydration alone
[235]. Several recent studies have employed the use of
NAC with other agents such as bicarbonate [236, 237],
hydration, and theophylline, with mixed results [70, 151,
237–240].
Several RCTs examining the role of NAC to prevent
renal dysfunction in other high-risk groups did not dem-
onstrate a beneficial effect of NAC regarding renal
dysfunction or need for renal support [241–245] (ESM
Table S9), although one study in 177 patients found a
mortality benefit for the patients treated with NAC [246].
It must be considered, though, that especially IV NAC
may be harmful, leading to allergic reactions [247] or
decreased cardiac output or survival in patients with
septic shock [248, 249].
A recent single-center trial showed a protective effect
of oral ascorbic acid on the development of contrast
nephropathy [250]. Here too, the rate of nephropathy in
the control group was high and no patients required renal
support. Two further studies investigating protection
against contrast nephropathy could not prove protective
effects of ascorbic acid [72, 251].
There have been several studies on antioxidant sup-
plementation in the ICU, although few large studies have
been conducted. The use of an antioxidant cocktail in
patients undergoing elective aortic aneurysm repair
resulted in an increased creatinine clearance on the sec-
ond postoperative day but the incidence of renal failure
was very low [252].
A a small RCT in 42 patients showed that selenium
supplementation decreased the requirement for RRT from
43% to 14% [253]. These findings, however, could not be
reproduced in a larger RCT using selenium in 249
patients with sepsis (SIC study) [254, 255]. More recent
studies in the critically ill demonstrated that, although
selenium supplementation increased both selenium and
glutathione peroxidase levels, there was no effect on the
requirement for RRT [256].
Extracorporeal therapies
Recommendations
1. We suggest periprocedural continuous veno-venous
hemofiltration (CVVH) in an ICU environment to limit
contrast nephropathy after coronary interventions in
high-risk patients with advanced chronic renal insuf-
ficiency (grade 2C).
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Rationale
Extracorporeal therapies may protect the kidney by
removal of substance(s) such as contrast, particularly in
patients with chronic renal insufficiency, because of the
higher contrast load delivered to the remaining nephrons.
The relative amount of contrast removal by hemofiltration
depends on the pore size of the filter [257], on hemofil-
tration dose, and on residual renal function. Control of
homeostasis or maintenance of fluid balance may be
equally important.
Clinical studies
Several studies have employed renal replacement tech-
niques in an attempt to limit contrast nephropathy.
Amongst those, three studies utilized periprocedural
hemodialysis, with variable benefit [258–261]. Prophy-
lactic CVVH was evaluated in a total of 114 patients at
high risk of contrast nephropathy undergoing coronary
intervention. The intervention group had a significantly
reduced mortality as well as a reduced need for continued
renal support, particularly in those with baseline creatinine
[300 lmol/l [262]. The same author performed a sec-
ond RCT in 92 patients, which demonstrated that only
combined pre- and postprocedural CVVH, and not post-
procedural CVVH alone, had any renoprotective effect
[263]. It should be emphasized that the patients receiving
CRRT were treated in ICU and those receiving hydration
alone were not, which raises the question of whether the
hemofiltration procedure itself or the preprocedural opti-
mization in the ICU environment led to a better outcome.
Other mechanisms such as pre- and periprocedural
hydration during CVVH, correction of acidosis or control
of fluid balance might be relevant [264, 265].
Renal replacement techniques have also been used to
ameliorate myoglobin-induced tubular damage in rhab-
domyolysis or to remove oxalate following ethylene
glycol ingestion. Finally, prophylactic use of extracor-
poreal treatments in oncology patients at high risk of
tumor lysis syndrome has been reported. This available
literature is limited to case reports and small case series
and no recommendation can be drawn. However, it should
be emphasized that fomepizole should be used as a first-
line treatment before attempting extracorporeal therapy in
cases of ethylene glycol intoxication as well as rasburi-
case following adequate volume expansion in order to
prevent tumor lysis syndrome before consideration of
extracorporeal therapy. Similarly, the use of extracorpo-
real techniques to remove myoglobin will require
membranes with a high cutoff [266], possibly used in
series for a minimal duration of 6 h, which is not readily
available [267–273]. Four studies have evaluated leuk-
odepletion during cardiopulmonary bypass [274–277],
with three suggesting a beneficial effect on renal function
[274–276].
Conclusions and summary
One of the major problems with any review discussing
AKI is the fact that definitions used in many publications
vary largely. As a consequence comparing studies is
fraught with difficulties and calls for uniformly applicable
indicators of severity of renal dysfunction, such as dura-
tion and degree of oliguria as well as dependence on renal
replacement techniques. Fortunately, initiatives in this
direction have recently been taken and should aid further
study [5, 278].
In order to prevent AKI, prompt resuscitation of the
circulation with fluids, inotropes, vasoconstrictors and/or
vasodilators is the primary aim and is recommended.
Volume expansion is recommended for the prevention of
AKI in states of true and suspected hypovolemia, but
uncontrolled volume expansion and the use of high-
molecular-weight HES preparations and dextrans should
be avoided. Following volume resuscitation hypotensive
patients should be given a vasoconstrictor which should
be titrated individually, with a mean target blood pres-
sure of 60–65 mmHg being adequate in most
individuals. Vasodilators are recommended if optimiza-
tion of cardiac output or reduction in hypertension is
required, and some dilators may be considered to pre-
vent deterioration of renal function under strict
hemodynamic control. Together with these measures a
review of all medications, with the cessation of those
known to be nephrotoxic (e.g., amphotericin B, amino-
glycosides), is mandatory.
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